Division of Gastrointestinal and General Surgery, Department of Surgery, Oregon Health and Science University, Portland, OR.
Division of Gastrointestinal and General Surgery, Department of Surgery, Oregon Health and Science University, Portland, OR.
J Am Coll Surg. 2014 May;218(5):1004-11. doi: 10.1016/j.jamcollsurg.2014.01.039. Epub 2014 Jan 24.
Current quality initiatives call for examination of at least 12 lymph nodes in curative colon cancer resections. The aim of this study was to determine if the number of nodes harvested has increased, and if the increased number nodes correlates with improved staging or overall survival.
A review of the Surveillance, Epidemiology, and End Results program database from 2004-2010 was performed. All patients who underwent colon cancer resection during this date range were analyzed. Number of nodes retrieved, patient stage, overall survival, and overall survival by stage were examined. Multivariable analysis controlled for stage, cancer site, age, year of diagnosis, and number of nodes retrieved. Improved staging was defined as increased detection of stage III patients.
A total of 147,076 patients met inclusion criteria. Median number of nodes analyzed increased sequentially with each year examined, from 12 in 2004 to 17 in 2010. Despite greater number of total nodes obtained and analyzed, there was no increase in the percentage of patients with positive nodes (stage III disease). On multivariable analysis, after controlling for stage, site of disease, age, and year of diagnosis, there was a slight overall survival benefit with increasing nodal retrieval (hazard ratio = 0.987 for each additional node removed; 95% CI, 0.986-0.988; p < 0.001).
Since quality initiatives have been put in place, there has been an increase in the number of nodes examined in colon cancer resections, but no improvement in staging. The improved survival seen with higher node counts was independent of stage, site of disease, patient age, and year of diagnosis.
目前的质量改进计划要求在根治性结肠癌切除术中检查至少 12 个淋巴结。本研究旨在确定是否增加了淋巴结的检出数量,以及增加的淋巴结数量是否与分期改善或总生存相关。
对 2004-2010 年期间监测、流行病学和最终结果(SEER)数据库进行了回顾性分析。分析了在此期间接受结肠癌切除术的所有患者。分析了检出的淋巴结数量、患者分期、总生存和各分期的总生存。多变量分析控制了分期、肿瘤部位、年龄、诊断年份和检出的淋巴结数量。分期改善定义为增加 III 期患者的检出。
共有 147076 名患者符合纳入标准。分析的淋巴结中位数随着每年检查而逐渐增加,从 2004 年的 12 个增加到 2010 年的 17 个。尽管获得和分析的总淋巴结数量增加,但阳性淋巴结(III 期疾病)患者的比例并未增加。多变量分析显示,在控制分期、疾病部位、年龄和诊断年份后,随着淋巴结检出数量的增加,总生存略有获益(每增加一个淋巴结去除的风险比为 0.987;95%CI,0.986-0.988;p < 0.001)。
自质量改进计划实施以来,结肠癌切除术中检查的淋巴结数量有所增加,但分期并未改善。随着淋巴结计数的增加,生存改善与分期、疾病部位、患者年龄和诊断年份无关。